CBS 2019
CBSMD教育中心
中 文

经导管主动脉瓣置换

Abstract

Recommended Article

Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion Online Quantitative Aortographic Assessment of Aortic Regurgitation After TAVR: Results of the OVAL Study Discrepancies in Measurement of the Thoracic Aorta: JACC Review Topic of the Week Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement: A Review Long-term outcome of prosthesis-patient mismatch after transcatheter aortic valve replacement Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement

Review ArticleVolume 74, Issue 16, October 2019

JOURNAL:J Am Coll Cardiol. Article Link

Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week

A Mangieri, C Montalto, E Poletti et al. Keywords: anticoagulation; aortic stenosis; bleeding direct oral anticoagulants; TAVR; transcatheter aortic valve replacement

ABSTRACT

A large amount of evidence supports the widespread use of transcatheter aortic valve replacement (TAVR) among patients who are at low to intermediate risk for surgery. However, several controversies exist about the optimal antithrombotic regimen to use in these patients. On the one hand, concerns about ischemic stroke, subclinical leaflet thrombosis, valve thrombosis, and long-term durability suggest the need for a stronger antithrombotic regimen to ensure a better patient and valve outcome. On the other hand, the high bleeding risk of this population and the current lack of strong evidence in favor of a more aggressive antithrombotic strategy require caution. This review analyzes the rationale of antithrombotic therapy in TAVR illustrating the present scenario and future perspectives.